The suicide rate among U.S. service members is alarmingly high, with a recent study of 1.3 million veterans reporting that the suicide risk is 41--61% higher for veterans than civilians ([@R1]). Studies suggest that warzone trauma, PTSD, and other post-deployment mental health problems put veterans at heightened risk for suicide relative to the general population ([@R2]). Although the biological mechanisms involved in this association are not yet well understood, converging lines of evidence implicate stress-related molecular alterations of the hypothalamic-pituitary-adrenal (HPA) axis as well as changes in brain morphology and neural function in the etiology of suicide ([@R3]). Furthermore, early adversity and exposure to traumatic stress have been linked to changes in the methylation status and transcriptional activity of genes that regulate HPA-axis function ([@R4], [@R5]). These changes are associated with lower glucocorticoid receptor expression, decreased glucocorticoid negative feedback responses to stress, and hypercortisolism ([@R6], [@R7]). Brain regions densely populated with glucocorticoid receptors, such as the prefrontal cortex and hippocampus, are especially vulnerable to neuronal damage and cell death as a result of these effects ([@R8]--[@R11]).

One recently identified gene that may play a critical role in this process is *SKA2* (spindle and kinetochore associated complex subunit 2). The SKA2 protein is implicated in chaperoning the glucocorticoid receptor from the cytoplasm into the nucleus and, by doing so, it serves as a moderator of negative feedback inhibition of the HPA axis and a neuroprotective function by enhancing activation of glucocorticoid receptors ([@R12]). The clinical relevance of the *SKA2* locus was recently demonstrated by an epigenome-wide analysis of post-mortem brain tissue conducted to identify genes associated with suicide. Guintivano et al. ([@R13]) showed that methylation of probe cg13989295 in the 3′ untranslated region (UTR) of *SKA2* in *prefrontal* neurons was associated with suicide, with suicide decedents showing greater DNA methylation and less *SKA2* expression in surrounding tissue than controls. They found that *SKA2* methylation in blood predicted suicidal ideation and reduced suppression of waking cortisol in clinical samples after controlling for genotype (which is correlated with cg13989295 methylation), concluding that methylation is a more proximal predictor than genotype. These findings provide preliminary evidence that DNA methylation of *SKA2* is an indicator of glucocorticoid signaling dysregulation and a potentially useful biomarker of suicide vulnerability. A recent independent study found decreased expression of *SKA2* in blood from violent suicide completers compared to non-suicidal controls ([@R14]), replicating the findings of Guintivano et al. An important next step is to determine whether epigenetic variability at *SKA2* is also associated with identifiable alterations in neural integrity in psychiatrically relevant regions of the brain and/or stress-related psychiatric disorders linked to suicide.

Thus, building on previous research on *SKA2*, the primary aims of this study were to examine whether *SKA2* methylation is associated with alterations in cortical thickness and suicide-related psychiatric symptoms, specifically PTSD and depression. We focused on cortical rather than subcortical structures (e.g., hippocampus), based on evidence of reduced expression of *SKA2* in prefrontal tissue of suicide patients. Based on evidence that the SKA2 protein may be involved in mitigating the neurotoxic effects of stress, we hypothesized that greater DNA methylation of the CpG site identified by Guintivano et al. would be associated with decreased cortical thickness in prefrontal brain regions. We also expected DNA methylation to be associated with greater PTSD and depression symptoms given their associations with suicide risk.

Methods {#S1}
=======

 {#S2}

### Sample {#S3}

The sample consisted of 200 white non-Hispanic service members of Operations Enduring Freedom, Iraqi Freedom, and New Dawn (OEF/OIF/OND) (see [Table 1](#T1){ref-type="table"} for sample characteristics).^[1](#FN2){ref-type="fn"}^ Participants were consecutively enrolled in the Translational Research Center for TBI and Stress Disorders, a VA RR&D Traumatic Brain Injury Center of Excellence at VA Boston Healthcare System. DNA methylation data were available for all 200 participants, and neuroimaging data were available for 152 of those participants. The final sample for neuroimaging analyses was 145 after excluding individuals with a history of moderate or severe TBI. Approval for the study was obtained from all relevant Institutional Review Boards and regulatory committees. After complete description of the study to the subjects, written informed consent was obtained.

Procedures {#S4}
----------

### DNA Genotyping and Methylation {#S5}

DNA was extracted from peripheral blood samples. Whole-genome genotyping data was obtained by hybridizing DNA samples to Illumina HumanOmni2.5--8 microarrays and scanning with an Illumina iScan System (Illumina, San Diego, CA). SNP imputation was performed using Impute2 ([@R15]) and 1000 genomes reference data (The 1000 Genomes Project Consortium). DNA methylation data was obtained by hybridizing bisulfite-modified DNA to Illumina HumanMethylation450K microarrays and scanning with an Illumina iScan System (Illumina, San Diego, CA). Details on genotyping and methylation methods are available in the [Supplementary Materials](#SD1){ref-type="supplementary-material"}.

Methylation analyses focused on the cytosine-guanine (CpG) dinucleotide implicated by Guintivano et al. (13; Illumina probe cg13989295) and the intervening SNP rs7208505. Because the cytosine (C) at this position of the CpG site measured by cg13989295 is one allele of the (C-T) SNP rs7208505, cg13989295 methylation is highly correlated with rs7208505 genotype. Given that the cytosine measured by cg13989295 is one allele of the SNP rs7208505, the number of alleles that can be methylated depends upon an individual's genotype (e.g., for the C/T genotype, methylation is possible at one allele). Thus, before evaluating whether methylation associates with the phenotypes of interest, it was prudent to take genotype into account (i.e., adjust for genotype), because the range of possible methylation levels (0--100%, typically) was correlated with genotype and thus restricted in some participants. See [supplementary materials](#SD1){ref-type="supplementary-material"} for associations between SNP and methylation ([Figure S1](#SD1){ref-type="supplementary-material"}). The estimated proportion of methylation (Beta-value) of cg13989295 was logit transformed prior to analysis.

### Morphometric Acquisition and Processing {#S6}

Structural imaging data were acquired on a 3T Siemens TIM TRIO whole-body MRI scanner. Two T1-weighted anatomical scans (voxel size = 1mm^3^, TR = 2530ms, TE = 3.32ms, FOV = 256x256, \# of slices = 176) were acquired and averaged to create a single high contrast-to-noise image. The standard Freesurfer v5.1 morphometric pipeline was computed, including reconstruction of the cortical mantle and spatial smoothing of 20mm FWHM. Cortical surface models were manually checked slice-by-slice and edited for accuracy.

Psychiatric Symptoms {#S7}
--------------------

### Posttraumatic Stress Disorder {#S8}

Current PTSD symptom severity and PTSD diagnosis were assessed by doctoral level psychologists using the Clinician Administered PTSD Scale ([@R16]). The frequency and intensity of each DSM-IV PTSD criterion were assessed for the month preceding the assessment. Severity scores were calculated by summing the frequency and intensity scores for all 17 symptoms. All participants endorsed a DSM-IV PTSD Criterion A event. One participant was missing PTSD data.

### Depression {#S9}

Current depression symptom severity was assessed via the 14-item total depression subscale of the self-report Depression Anxiety Stress Scale (DASS; 17). Current Major Depressive Disorder (MDD) diagnosis was assessed by doctoral level psychologists using the Structured Clinical Interview for DSM-IV Axis I Disorders ([@R18]). Twelve participants were missing the DASS, and one participant was missing MDD diagnosis information.

Data Analysis {#S10}
-------------

The data analytic approach was based on Guintivano et al. ([@R13]). For each phenotype, we examined associations with rs7208505 genotype, cg13989295 methylation, and methylation adjusted for genotype. Methylation adjusted for genotype (methylation~adj~) was calculated by taking the residuals of a linear model of *SKA2* 3′ UTR DNA methylation as a function of rs7208505 genotype. All statistical models were adjusted for age, sex, and population substructure (as indexed by the first three ancestry principal components). Associations between methylation level (unadjusted) and each psychiatric/brain phenotype are presented separately by genotype in the [supplemental materials](#SD1){ref-type="supplementary-material"} for reference ([Table S1](#SD1){ref-type="supplementary-material"} and [Figure S2](#SD1){ref-type="supplementary-material"}). Cell counts were estimated from the methylation data, and analyses using these cell counts were performed to rule out cell composition as a potential confound. Unless otherwise specified, reported methylation~adj~ results remained significant when cell composition estimates were included in the model. All tests were two-tailed.

We computed vertex-wise analyses across the entire cortex to test the hypothesis that *SKA2* methylation would be associated with reduced cortical integrity in prefrontal brain regions. General linear model analyses were run using FreeSurfer's Qdec. Vertex-wise significance threshold was set at *p* \< .01. Monte Carlo simulations (10,000 iterations) were used to correct for multiple comparisons, resulting in a whole brain corrected threshold of *p* \< .05. Only regions surviving correction for multiple comparisons are reported.

*SKA2* methylation associations with suicide-related psychiatric phenotypes were assessed using hierarchical linear regression models in SPSS v22 (SPSS, Chicago, IL). Mediation analyses were conducted in Mplus 7.11 ([@R19]) in the subsample with complete data (*n* = 144) using the maximum likelihood estimator with bootstrapped standard errors and confidence intervals. All brain region phenotypes were examined simultaneously in the model such that each was regressed on methylation, psychiatric phenotype, and rs7208505 genotype. Methylation was also regressed on genotype and psychiatric phenotype. The indirect effect of psychiatric phenotype on the brain phenotypes via methylation was assessed using the 'model indirect' procedure.

Results {#S11}
=======

*SKA2* Associations with Cortical Thickness {#S12}
-------------------------------------------

The genotype at rs7208505 did not relate to cortical thickness in the whole brain analyses nor did methylation. As hypothesized, however, *SKA2* methylation~adj~ was associated with reduced cortical thickness in prefrontal cortex. Three clusters survived correction for multiple comparisons ([Table 2](#T2){ref-type="table"}, [Figure 1](#F1){ref-type="fig"}). A left hemisphere cluster spanned frontal pole and the anterior aspects of superior frontal gyrus (SFG) and rostral middle frontal gyrus (MFG) (BA 9/10). Two clusters also emerged in right PFC: one spanning right frontal pole and anterior SFG (BA 9/10) and one in (lateral and medial) orbitofrontal cortex (OFC) and the anterior aspects of inferior frontal gyrus pars orbitalis and rostral MFG (BA 10/11). Greater *SKA2* methylation~adj~ was associated with decreased cortical thickness in all clusters (*rs* \< −.28, *ps* \<.001). These results were consistent with those of a similar analysis in rs7208505 genotype groups ([Figure S2](#SD1){ref-type="supplementary-material"} and [Table S1](#SD1){ref-type="supplementary-material"}).

To examine the clinical significance of the alterations in brain morphology associated with *SKA2* epigenetic variation, we correlated mean cortical thickness for each cluster with measures of PTSD and depression. PTSD symptom severity was negatively correlated with cortical thickness in both right prefrontal clusters (*rs* \< −.20, *ps* \<.018) and showed a trend for the left prefrontal cluster (*r* = −.16, *p* = .06). In contrast, current depression symptom severity was unrelated to cortical thickness in any of the clusters. Analyses performed using dichotomous indices of PTSD and MDD diagnosis produced a similar pattern of results.^[2](#FN3){ref-type="fn"}^

To rule out potential confounds, we tested whether findings were due to the influence of comorbid substance use disorders, psychiatric medication use, or mild TBI (individuals with moderate/severe TBI were already excluded from analyses). We extracted each brain cluster and ran a hierarchical linear regression analysis with these variables added to the statistical models. The associations between DNA methylation~adj~ and cortical thickness for each of the clusters remained significant when these potential confounds were included in the models (*ps* \< .002).

*SKA2* Associations with Psychiatric Symptoms {#S13}
---------------------------------------------

We next examined whether genetic and epigenetic variation at *SKA2* associated with psychiatric symptoms that increase risk of suicide -- specifically PTSD and depression. Linear regression models revealed that rs7208505 genotype was associated with current PTSD symptom severity (*β* = −.16, *p* = .028), such that individuals homozygous for the C minor allele had lower PTSD symptom severity than heterozygotes (*M~Difference~* = −16.5, *p* = .013) and T/T carriers (*M~Difference~* = −15.8, *p* = .024). Methylation was not associated with PTSD, but methylation~adj~ was associated with PTSD symptom severity over and above the effect of genotype (*β* = .37, *p* = .021), with methylation~adj~ correlating positively with current PTSD symptoms (see [Table 3](#T3){ref-type="table"}). Genetic and epigenetic variations at *SKA2* were not associated with depression symptoms. Analyses performed using PTSD and MDD diagnostic status yielded a similar pattern of results.^[3](#FN4){ref-type="fn"}^

*SKA2* Epigenetic Variation as a Mediator of Brain-Behavior Relationships {#S14}
-------------------------------------------------------------------------

Based on the findings above, we tested whether *SKA2* methylation~adj~ mediated the observed association between PTSD symptom severity and reduced cortical thickness in the prefrontal clusters. All phenotypes were examined simultaneously in one model. The indirect effect of PTSD on the right OFC/rostral MFG cluster through DNA methylation~adj~ was significant (standardized *β* = −.067, *p* = .039, 95% CI = −.131 to −.003), as was the corresponding effect on the left prefrontal cluster (standardized *β* = −.063, *p* = .043, 95% CI = −.125 to −.002). The effect was not statistically significant for the right frontal pole/SFG cluster, although the direction of association was consistent (standardized *β* = −.061, *p* = .056, 95% CI = −.124 to .002). In total, the model explained 82% of the variance in methylation, and 16% of the variance in each of the three brain clusters.

Discussion {#S15}
==========

This study extended the link between *SKA2* DNA methylation and suicide by examining associations between this novel epigenetic risk locus, cortical thickness, and suicide-related psychiatric symptoms. We hypothesized that greater DNA methylation at *SKA2* would be associated with decreased cortical thickness in prefrontal brain regions in trauma-exposed veterans. Whole-brain vertex-wise analyses revealed that *SKA2* methylation~adj~ at this locus was associated with diminished cortical thickness in three regions of prefrontal cortex, and reduced thickness in these regions corresponded to more severe current PTSD symptoms. Although causality cannot be inferred from this cross-sectional dataset, path analysis showed that *SKA2* methylation~adj~ significantly mediated the relationship between PTSD and neural integrity in prefrontal cortex. These findings extend previous work by linking *SKA2* methylation~adj~ to alterations in cortical thickness - a possible brain endophenotype of stress-related suicide risk - and broaden its potential clinical utility by pointing to its value as a possible PTSD biomarker.

The association between *SKA2* methylation~adj~ and reductions in cortical thickness provides novel insight into how alterations in stress-sensitive molecular pathways impact neural integrity and function. In both hemispheres, greater methylation~adj~ was associated with reduced cortical thickness in frontal pole and the anterior aspects of SFG and rostral MFG, areas of the brain crucial for several high-level cognitive-control processes. Specifically, meta-analytic evidence ([@R20]) indicates that the observed clusters (i.e., BA 9/10) are involved in multitask control (e.g., holding one task online while performing a separate task), which is necessary for evaluating multiple choices at once, complex reasoning, and cognitive flexibility. Burgess and colleagues ([@R21]) have proposed a 'gateway' hypothesis, in which these regions coordinate behavior by biasing attention toward internal mental stimuli (thoughts, emotions) or external sensory information. Additionally, frontal pole in particular has been implicated in prospective thinking and introspection ([@R22], [@R23]). Disruption of these higher-order control processes may lead to impulsive decision-making, difficulty imagining future prospects, and emotional dysregulation, which are all risk factors for suicidal behavior ([@R3], [@R24], [@R25]). An additional cluster emerged in regions of right OFC and IFG pars orbitalis ([Figure 1](#F1){ref-type="fig"}) thought to be crucial for maintaining, updating, and adjusting ongoing behavior based on reward and punishment contingencies ([@R26]). Reduced integrity in these regions has been linked to emotional dysregulation and impulsivity ([@R27]--[@R29]). Given the cognitive functions subserved, reduced cortical integrity in the identified prefrontal clusters may represent a significant neurobiological vulnerability for suicidal behavior in the context of stress-related psychiatric illnesses, an important question that can be addressed in future research that explicitly examines suicidal behavior.

Given that the SKA2 protein has not been studied extensively, the exact mechanisms by which *SKA2* may impact cortical integrity are unknown. However, studies suggest that it interacts with the glucocorticoid receptor by chaperoning it from the cytoplasm to the nucleus and is a moderator of negative feedback inhibition of cortisol by the glucocorticoid receptor ([@R12]). In prefrontal cortex, where glucocorticoid receptor density is enriched ([@R9]), sustained elevations of cortisol can cause neuronal damage and cell death either directly ([@R30]--[@R32]) or indirectly through mechanisms such as oxidative stress ([@R33]). Thus, *SKA2* expression may serve a neuroprotective function by enhancing activation of the glucocorticoid receptor. This, in turn, up-regulates the expression of anti-inflammatory proteins in neuronal nuclei, represses the expression of pro-inflammatory proteins in the cytosol, and mitigates oxidative stress. These functions are similar to that of the better-known FK506 binding protein 5 (FKBP5), a co-chaperone of the glucocorticoid receptor, which has been linked in genetic association studies to a variety of relevant phenotypes including PTSD ([@R34]), alterations of brain morphology ([@R35], [@R36]) and suicide ([@R37], [@R38]). Epigenetic variation at *SKA2,* therefore, may represent an important additional locus that confers individual differences in risk and resilience to stress.

Although there are compelling data that *SKA2* plays a role in suicide ([@R13], [@R14]), the present findings suggest it is also relevant for understanding the pathophysiology of stress-related disorders more broadly. By associating methylation at this locus with reduced thickness in prefrontal cortex, this study implicates a molecular and neurobiological pathway by which prolonged or extreme stress exposure impacts susceptibility for psychiatric disorders. More precisely, *SKA2* may index a transdiagnostic susceptibility to neural deterioration from stress exposure, with suicide and PTSD being two clinical outcomes in which stress exposure is a potent etiological factor, and thus highly relevant. Although novel to *SKA2*, these hypotheses are consistent with research on the neurotoxic effects of stress exposure ([@R9], [@R39]), including in relation to suicide and PTSD ([@R33], [@R40]).

Moving forward, an important next step will be to focus on clarifying how alterations in stress-sensitive molecular and neurobiological pathways interact with other biological, psychological, and social risk processes to promote suicidal behavior. Not all individuals with stress-related disorders ultimately die by suicide, and thus, examination of more comprehensive etiological models will be needed to individualize risk assessment measures and intervene effectively. For example, present findings suggest that epigenetic modifications from stress exposure may compromise the neural circuits that typically support adaptive decision-making and self-regulation. Expansion of this work to clarify how these molecular and neural mechanisms interact with putative endophenotypes for suicide risk, including HPA-axis dysregulation, serotonin dysfunction, and aberrant cognitive-affective processes (e.g., impulsive-aggressive traits, disadvantageous decision-making), as well as stressful life events and functional genetic/epigenetic influences ([@R41], [@R42]) could elucidate heterogeneity in pathways to suicidal behavior and improve the precision of risk models.

The findings and conclusions need to be considered in the context of the study limitations. First, our results indicate that adjusting methylation levels by the methylation-associated SNP revealed associations that were not apparent for unadjusted methylation or the local SNP. Indeed, no significant relationships were observed for unadjusted methylation at the cg13989295 probe, and no new results emerged for rs7208505 that were not also present for adjusted methylation (i.e., a main effect of SNP was only observed for PTSD). Although we did not observe effects for unadjusted methylation, Guintivano et al. ([@R13]) reported associations between DNA methylation and *SKA2* expression in brain tissue both before and after controlling for genotype. These discrepant findings for unadjusted methylation may be due to differences in measuring DNA methylation in peripheral blood samples versus brain tissue, which is beyond the scope of the present study but an important avenue of future inquiry. Further, given that it is not clear what adjusting methylation for genotype implies on a biological level and research on *SKA2* is in its infancy, further investigation is needed to clarify the functional significance and biological implications of this analytic method. In particular, whether adjusted methylation in blood reflects a specific causal mechanism underlying alterations in neural structure/function or rather serves as a useful indicator of biological processes related to stress exposure and susceptibility more broadly has yet to be determined.

Second, the cross-sectional nature of our data prohibits strong conclusions regarding the direction of the proposed effects, and other mediational models are certainly possibly. We tested *SKA2* methylation as a mediator of the association between PTSD (as a measure of ongoing stress) on neural integrity (effects of stress on the brain), but it is also possible that brain phenotypes may mediate the association between methylation and PTSD or that alterations in cortical thickness cause HPA-axis dysregulation and thus alter *SKA2* methylation. Thus, prospective research is needed to ascertain the mechanism(s) by which traumatic stress impacts epigenetic variation and neural integrity. Third, the absence of an association between depression symptoms and *SKA2* variation in this sample should be interpreted in the context of both the modest size and the makeup of our sample. Given that *SKA2* purportedly measures a stress-specific molecular pathway, the high levels of trauma exposure in this sample may have strengthened our ability to detect PTSD effects. However, it is also possible that methylation at *SKA2* is less predictive of depression than PTSD phenotypes, and this hypothesis requires testing in larger and more diverse samples. Fourth, we do not have information about the stability of the methylation level of this gene, and prospective studies are needed to ascertain how methylation levels vary over time. Finally, it is important to note that a measure of suicidal behavior was not included in this study, and thus, the findings can only speak to the implications for understanding suicide-related risk processes indirectly, through connections from previous research on *SKA2* ([@R13], [@R14]). Despite these limitations, this study also has several strengths, most notably the clinically-relevant sample of veterans with trauma exposure and the innovative research design that integrates neuroimaging and genetic methods to study the biology of stress-related psychiatric phenotypes.

In summary, findings advance our understanding of stress susceptibility for psychiatric disorders by identifying *SKA2* as a potential biomarker of the effects of stress exposure on cortical thickness in psychiatrically relevant brain regions. As a putative molecular measure of cumulative dysregulation in stress response systems, *SKA2* epigenetic variation may be a useful blood biomarker for screening military personnel prior to deployment to identify individuals with a high lifetime burden of stress who are at risk for developing PTSD and suicide following exposure to warzone stress.
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Three individuals with methylation levels greater than 3 SDs from the sample mean for each genotype were excluded from the study, resulting in a final *N* of 200. Supplemental analyses indicated that including these cases did not change the study findings.

Current PTSD diagnosis was associated with decreased cortical thickness in the right frontal pole/SFG cluster (*F*~1,\ 143~ = 4.75, *p* = .031) and right OFC/IFG/rostral MFG cluster (*F*~1,\ 143~ = 6.25, *p* = .014), with a trend emerging for the left frontal cluster (*F*~1,\ 143~ = 3.39, *p* = .068). Cortical thickness in these clusters did not differ by MDD diagnostic status (*F*~1,\ 143s~ \< 1.42, *ps* \> .23).

DNA methylation~adj~ was associated with a greater likelihood of current PTSD diagnosis (*Wald χ2* = 4.35, OR = 1.2, *p* = .037), but not current MDD diagnosis. However, the relationship between DNA methylation~adj~ and PTSD diagnosis were reduced to a trend-level when cell counts were entered in the model (*Wald χ2* = 2.75, OR = 1.1, *p* = .097).
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![SKA2 Methylation Adjusting for Genotype Relates to Reduced Cortical Thickness in Frontal Cortex\
(A) Frontal pole, superior frontal gyrus, and rostral middle frontal gyrus. (B) Frontal pole and superior frontal gyrus. (C) Orbitofrontal cortex, inferior frontal gyrus, and rostral middle frontal gyrus.](nihms712223f1){#F1}

###### 

Characteristics of OEF/OIF/OND Trauma-Exposed Veteran Study Sample

                                                              Mean (SD)    N (%)
  ----------------------------------------------------------- ------------ -----------
  Age (Years)                                                 31.8 (8.4)   
  Sex (Male)                                                  \-           182 (91%)
  Military Deployment Duration (Months)                       12.9 (8.7)   \-
  Psychiatric Medication Use[a](#TFN2){ref-type="table-fn"}                
   No                                                                      108 (54%)
   Yes                                                                     88 (44%)
  Current PTSD[b](#TFN3){ref-type="table-fn"}                 \-           
   No                                                                      83 (41%)
   Yes                                                                     116 (58%)
  Current MDD[b](#TFN3){ref-type="table-fn"}                  \-           
   No                                                                      150 (75%)
   Yes                                                                     49 (25%)
  Current SUD[b](#TFN3){ref-type="table-fn"}                  \-           
   No                                                                      171 (86%)
   Yes                                                                     28 (14%)

*Note.* PTSD = posttraumatic stress disorder. MDD = major depressive disorder. SUD = substance use disorder.

four missing cases.

one missing case.

###### 

Reductions in Cortical Thickness in Frontal Cortex Associated with SKA2 3′ UTR DNA Methylation Adjusting for Genotype

                                         Peak F-Value   Peak (x,y,z)   No. of Vertices   Cluster Size (mm^2^)
  -------------------------------------- -------------- -------------- ----------------- ----------------------
  L Frontal Pole/SFG/Rostral MFG         −2.87          −8, 61, 12     121563            1832
  R Frontal Pole/SFG                     −3.49          7, 55, 25      64286             1347
  R OFC/IFG Pars Orbitalis/Rostral MFG   −3.17          27, 49, −12    64226             1411

*Note: N* = 145. SFG = superior frontal gyrus. MFG = middle frontal gyrus. OFC = orbitofrontal cortex. IFG = inferior frontal gyrus. All clusters survived Monte Carlo Simulation correction for multiple comparisons. R = right hemisphere. L = left hemisphere.

###### 

Hierarchical Linear Regression Analysis of Genetic and Epigenetic Variation at SKA2 and Current PTSD Symptom Severity

                                               Model 1                                       Model 2                                       Model 3
  -------------------------------------------- --------------------------------------------- --------------------------------------------- ---------------------------------------------
  Step 1                                                                                                                                   
   Age                                         −.10 (0.3)                                    −.10 (0.3)                                    −.10 (0.3)
   Sex                                         .04 (7.3)                                     .04 (7.3)                                     .04 (7.3)
   Ancestry PC1                                .02 (29.9)                                    .02 (29.9)                                    .02 (29.9)
   Ancestry PC2                                .08 (30.1)                                    .08 (30.1)                                    .08 (30.1)
   Ancestry PC3                                −.16 (30.1)[\*](#TFN9){ref-type="table-fn"}   −.16 (30.1)[\*](#TFN9){ref-type="table-fn"}   −.16 (30.1)[\*](#TFN9){ref-type="table-fn"}
  Step 2                                                                                                                                   
   rs7208505 Genotype                          −.16 (2.9)[\*](#TFN9){ref-type="table-fn"}    \-\-\-\-\-\-\--                               −.16 (2.9)[\*](#TFN9){ref-type="table-fn"}
   cg13989295 Methylation                      \-\-\-\-\-\-\--                               −.07 (0.4)                                    \-\-\-\-\-\-\--
  Step 3                                                                                                                                   
   cg13989295 Methylation (methylation~adj~)   \-\-\-\-\-\-\--                               \-\-\-\-\-\-\--                               .37 (0.9)[\*](#TFN9){ref-type="table-fn"}

*Note. N* = 199. PC = principal component.

Model 1. Step1: *R^2^*= .043, Step2: Δ *R^2^*= .024\*.

Model 2. Step1: *R^2^*= .043, Step2: Δ *R^2^*= .01.

Model 3. Step1: *R^2^*= .043, Step2: Δ *R^2^*= .024\*, Step3: Δ *R^2^*= .026\*.

*p* \<.05.
